PacBio Q4 revenue $44.6M (+14% YoY); full year $160M (+4%); record consumables

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2025-FY EPS reported -$1.82 revenue$160,005,000

Q4 2025 revenue ~$44.6M vs $39.2M YoY; full year ~$160M vs $154M.
Instrument revenue Q4 ~$17.3M (Q4'24 $15.3M); consumables ~$21.6M (Q4'24 $18.8M) a record.
Vega placements 42 in Q4 vs 7 a year ago; Revio placements 21 vs 23.
Ending cash $279.5M vs $389.9M; management cites reduced cash burn and SPRQ-Nx catalyst.
PacBio presents at J.P. Morgan Healthcare Conference on Jan 12, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.